Tuy nhin, cc th nghim cho thy GHS c tc dng gip lm gim cc triu chng run, kh cm nm ca bnh l
Statements Author contributions ZL: Conceptualization, Validation, Writing original draft
In the CY 2025 PFS final rule (89 FR 98293), we stated that we would explore avenues to implement section 1860D-14B(b)(1)(B) of the Act, ( which requires the exclusion from the total number of units for a Part D rebatable drug those units for which a manufacturer provided a discount under the 340B Program starting January 1, 2026, through the establishment of a repository
In: Coenzyme Q in aging 5189 Shu DY, Chaudhary S, Cho K-S, Lennikov A, Miller WP, Thorn DC, Yang M, McKay TB (2023) Role of oxidative stress in ocular diseases: a balancing act
doi: 10.1016/S1553-7250(14)40021-7